Nanoparticle-mediated drug delivery systems (DDS) in the central nervous system

Current Organic Chemistry

Volumn 21, Issue 3, 2017, Pages 272-283

  Zhang, Guilong ^a   Chen, Lukui ^a   Guo, Xiaoyuan ^a   Khan, Ahsan A ^a   Gu, Yuchun ^b,c   Gu, Ning ^d  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b ASTON UNIVERSITY   (United Kingdom)

^c PEKING UNIVERSITY   (China)

^d SOUTHEAST UNIVERSITY   (China)

Author keywords

Blood brain barrier; Central nervous system; Drug delivery system; Nanoparticle

Indexed keywords

BLOOD; CONTROLLED DRUG DELIVERY; NANOMAGNETICS; NANOPARTICLES; NEUROPHYSIOLOGY; SILICA; TARGETED DRUG DELIVERY; YARN;

BIOMEDICAL FIELDS; BLOOD-BRAIN BARRIER; BRAIN LESIONS; CENTRAL NERVOUS SYSTEMS; CYTOTOXIC; DRUG-DELIVERY SYSTEMS; EFFICIENT DRUG DELIVERY; LIPID NANOCARRIER; NANOCARRIERS; SYSTEM STRATEGIES;

NANOSTRUCTURED MATERIALS;

EID: 85032799651     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/1385272820666161017170325     Document Type: Review

References (144)

1. Stockwell, J.; Abdi, N.; Lu, X.F.; Maheshwari, O.; Taghibiglou, C. Novel central nervous system drug delivery systems. Chem. Biol. Drug Des., 2014, 83(5), 507-520.
2. Capek, I. Viral nanoparticles, noble metal decorated viruses and their nano-conjugates. Adv. Coll. Interface Sci., 2015, 222, 119-134.
3. Wen, A.M.; Steinmetz, N.F. Design of virus-based nanomaterials for medicine, biotechnology, and energy. Chem. Soc. Rev., 2016, 45(15), 4074-4126.
4. Shityakov, S.; Salmas, R.E.; Salvador, E.; Roewer, N.; Broscheit, J.; Forster, C. Evaluation of the potential toxicity of unmodified and modified cyclodextrins on murine blood-brain barrier endothelial cells. J. Toxicol. Sci., 2016, 41(2), 175-184.
5. Shityakov, S.; Puskas, I.; Papai, K.; Salvador, E.; Roewer, N.; Forster, C.; Broscheit, J.A. Sevoflurane-sulfobutylether-beta-cyclodextrin complex: Preparation, characterization, cellular toxicity, molecular modeling and blood-brain barrier transport studies. Molecules, 2015, 20(6), 10264-10279.
6. Shityakov, S.; Salvador, E.; Pastorin, G.; Forster, C. Blood-brain barrier transport studies, aggregation, and molecular dynamics simulation of multi-walled carbon nanotube functionalized with fluorescein isothiocyanate. Int. J. Nanomed., 2015, 10, 1703-1713.
7. Shityakov, S.; Broscheit, J.; Forster, C. Alpha-cyclodextrin dimer complexes of dopamine and levodopa derivatives to assess drug delivery to the central nervous system: ADME and molecular docking studies. Int. J. Nanomed., 2012, 7, 3211-3219.
8. Santos, T.; Ferreira, R.; Maia, J.; Agasse, F.; Xapelli, S.; Cortes, L.; Bra-ganca, J.; Malva, J.O.; Ferreira, L.; Bernardino, L. Polymeric nanoparticles to control the differentiation of neural stem cells in the subventricular zone of the brain. ACS Nano, 2012, 6(12), 10463-10474.
9. Kong, S.D.; Lee, J.; Ramachandran, S.; Eliceiri, B.P.; Shubayev, V.I.; Lal, R.; Jin, S. Magnetic targeting of nanoparticles across the intact blood-brain barrier. J. Control Release, 2012, 164(1), 49-57.
10. Joshi, M.D.; Muller, R.H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm., 2009, 71(2), 161-172.
11. Tagalakis, A.D.; Kenny, G.D.; Bienemann, A.S.; McCarthy, D.; Munye, M.M.; Taylor, H.; Wyatt, M.J.; Lythgoe, M.F.; White, E.A.; Hart, S.L. PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes. J. Control Release, 2014, 174, 177-187.
12. Silva, G.A. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC Neurosci., 2008, 9.
13. Amiri, H.; Saeidi, K.; Borhani, P.; Manafirad, A.; Ghavami, M.; Zerbi, V., Alzheimer's Disease: Pathophysiology and applications of magnetic nanoparticles as mri theranostic agents. ACS Chem. Neurosci., 2013, 4(11), 1417-1429.
14. Martino, G.; Pluchino, S. Neural stem cells: Guardians of the brain. Nat. Cell Biol., 2007, 9(9), 1031-1034.
15. Schrofel, A.; Kratosova, G.; Safarik, I.; Safarikova, M.; Raska, I.; Shor, L.M. Applications of biosynthesized metallic nanoparticles - A review. Acta Bio-materialia, 2014, 10(10), 4023-4042.
16. Cole, J.T.; Holland, N.B. Multifunctional nanoparticles for use in theranostic applications. Drug Deliv. Trans. Res., 2015, 5(3), 295-309.
17. Denora, N.; Trapani, A.; Laquintana, V.; Lopedota, A.; Trapani, G. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain. Curr. Top. Med. Chem., 2009, 9(2), 182-196.
18. Gao, H.L.; Pang, Z.Q.; Jiang, X.G. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm. Res. Dordr., 2013, 30(10), 2485-2498.
19. Van Rooy, I.; Cakir-Tascioglu, S.; Hennink, W.E.; Storm, G.; Schiffelers, R.M.; Mastrobattista, E. In vivo methods to study uptake of nanoparticles into the brain. Pharm. Res. Dordr., 2011, 28(3), 456-471.
20. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Ipe, B.I.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25(10), 1165-1170.
21. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42(6), 463-478.
22. Garbayo, E.; Ansorena, E.; Blanco-Prieto, M.J. Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems. Maturitas, 2013, 76(3), 272-278.
23. Polak, P.; Shefi, O. Nanometric agents in the service of neuroscience: Manipulation of neuronal growth and activity using nanoparticles. Nanomed. Nanotech. Biol. Med., 2015, 11(6), 1467-1479.
24. Eamegdool, S.S.; Weible, M.W.; Pham, B.T.T.; Hawkett, B.S.; Grieve, S.M.; Chan-Ling, T. Ultrasmall superparamagnetic iron oxide nanoparticle prela-belling of human neural precursor cells. Biomaterials, 2014, 35(21), 5549-5564.
25. Sefton, M.V.; Babensee, J.E.; Woodhouse, K.A. Innate and adaptive immune responses in tissue engineering. Semin. Immunol., 2008, 20(2), 83-85.
26. Wong, H.L.; Wu, X.Y.; Bendayan, R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev., 2012, 64(7), 686-700.
27. Biddlestone-Thorpe, L.; Marchi, N.; Guo, K.; Ghosh, C.; Janigro, D.; Valerie, K.; Yang, H. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv. Drug Deliv. Rev., 2012, 64(7), 605-613.
28. Gunawardena, S. Nanoparticles in the brain: A Potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases. Pharm. Res. Dordr., 2013, 30(10), 2459-2474.
29. Lesniak, M.S.; Brem, H. Targeted therapy for brain tumours. Nat. Rev. Drug. Discov., 2004, 3(6), 499-508.
30. Roney, C.; Kulkarni, P.; Arora, V.; Antich, P.; Bonte, F.; Wu, A.; Mallikar-juana, N.N.; Manohar, S.; Liang, H.F.; Kulkarni, A.R.; Sung, H.W.; Sairam, M.; Aminabhavi, T.M. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Control Release, 2005, 108(2-3), 193-214.
31. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control Release, 2012, 161(2), 264-273.
32. Alyautdin, R.; Khalin, I.; Nafeeza, M.I.; Haron, M.H.; Kuznetsov, D. Nanoscale drug delivery systems and the blood-brain barrier. Int. J. Nanomed., 2014, 9, 795-811.
33. Begley, D.J. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol., 1996, 48(2), 136-146.
34. Begley, D.J. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol. Therapeutics, 2004, 104(1), 29-45.
35. Bernacki, J.; Dobrowolska, A.; Nierwinska, K.; Malecki, A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol. Rep., 2008, 60(5), 600-622.
36. Aguzzi, A.; Barres, B.; Bennett, M.L. Microglia: Scapegoat, saboteur, or something else? Science, 2013, 339(6116), 156-161.
37. Daneman, R.; Rescigno, M. The gut immune barrier and the blood-brain barrier: Are they so different? Immunity, 2009, 31(5), 722-735.
38. Banks, W.A. Blood-brain barrier as a regulatory interface. Forum. Nutr., 2010, 63, 102-110.
39. Abbott, N.J.; Patabendige, A.A.K.; Dolman, D.E.M.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Disease, 2010, 37(1), 13-25.
40. Abbott, N.J.; Romero, I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today, 1996, 2(3), 106-113.
41. Stojanov, K.; Zuhorn, I.S.; Dierckx, R.A.J.O.; De Vries, E.F.J. Imaging of cells and nanoparticles: Implications for drug delivery to the brain. Pharm. Res. Dordr., 2012, 29(12), 3213-3234.
42. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263(5153), 1600-1603.
43. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55(3), 329-347.
44. Danhier, F.; Ansorena, E.; Silva, J.M.; Coco, R.; Le Breton, A.; Preat, V. PLGA-based nanoparticles: An overview of biomedical applications. J. Control Release, 2012, 161(2), 505-522.
45. Semete, B.; Booysen, L.; Lemmer, Y.; Kalombo, L.; Katata, L.; Verschoor, J.; Swai, H.S. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed. Nanotechnol., 2010, 6(5), 662-671.
46. Dechy-Cabaret, O.; Martin-Vaca, B.; Bourissou, D. Controlled ring-opening polymerization of lactide and glycolide. Chem. Rev., 2004, 104(12), 6147-6176.
47. Huang, R.Q.; Qu, Y.H.; Ke, W.L.; Zhu, J.H.; Pei, Y.Y.; Jiang, C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyle-neglycol-modified polyamidoamine dendrimer. Faseb. J., 2007, 21(4), 1117-1125.
48. Yemisci, M.; Caban, S.; Gursoy-Ozdemir, Y.; Lule, S.; Novoa-Carballal, R.; Riguera, R.; Fernandez-Megia, E.; Andrieux, K.; Couvreur, P.; Capan, Y.; Dalkara, T. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J. Cerebral Blood Flow Metabol., 2015, 35(3), 469-475.
49. Calvo, P.; Gouritin, B.; Chacun, H.; Desmaele, D.; D'Angelo, J.; Noel, J.P.; Georgin, D.; Fattal, E.; Andreux, J.P.; Couvreur, P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. Dordr., 2001, 18(8), 1157-1166.
50. Hans, M.; Shimoni, K.; Danino, D.; Siegel, S.J.; Lowman, A. Synthesis and characterization of mPEG-PLA prodrug micelles. Biomacromolecules, 2005, 6(5), 2708-2717.
51. Su, Z.G.; Xing, L.; Chen, Y.N.; Xu, Y.R.; Yang, F.F.; Zhang, C.; Ping, Q.N.; Xiao, Y.Y. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas. Mol. Pharmaceut., 2014, 11(6), 1823-1834.
52. Xia, H.M.; Gao, X.L.; Gu, G.Z.; Liu, Z.Y.; Hu, Q.Y.; Tu, Y.F.; Song, Q.X.; Yao, L.; Pang, Z.Q.; Jiang, X.G.; Chen, J.; Chen, H.Z. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int. J. Pharmaceut., 2012, 436(1-2), 840-850.
53. Guo, W.H.; Li, A.M.; Jia, Z.J.; Yuan, Y.; Dai, H.F.; Li, H.X. Transferrin modified PEG-PLA-resveratrol conjugates: In vitro and in vivo studies for glioma. European. J. Pharmacol., 2013, 718(1-3), 41-47.
54. Li, L.H.; Guo, K.; Lu, J.; Venkatraman, S.S.; Luo, D.; Ng, K.C.; Ling, E.A.; Moochhala, S.; Yang, Y.Y. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials, 2008, 29(10), 1509-1517.
55. Liu, X.; An, C.Y.; Jin, P.; Liu, X.S.; Wang, L.H. Protective effects of cati-onic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomaterials, 2013, 34(3), 817-830.
56. Magzoub, M.; Eriksson, L.E.G.; Graslund, A. Conformational states of the cell-penetrating peptide penetratin when interacting with phospholipid vesicles: effects of surface charge and peptide concentration. Bba-Biomembrane., 2002, 1563(1-2), 53-63.
57. Di Toro, R.; Betti, V.; Spampinato, S. Biocompatibility and integrin-mediated adhesion of human osteoblasts to poly(DL-lactide-co-glycolide) copolymers. Eur. J. Pharm. Sci., 2004, 21(2-3), 161-169.
58. Zhang, X.; Chen, G.; Wen, L.; Yang, F.; Shao, A.L.; Li, X.; Long, W.; Mu, L. Novel multiple agents loaded PLGA nanoparticles for brain delivery via inner ear administration: In vitro and in vivo evaluation. Eur. J. Pharm. Sci., 2013, 48(4-5), 595-603.
59. Kirby, B.P.; Pabari, R.; Chen, C.N.; Al Baharna, M.; Walsh, J.; Ramtoola, Z. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of lopera-mide. J. Pharm. Pharmacol., 2013, 65(10), 1473-1481.
60. Tao, H.Q.; Meng, Q.F.; Li, M.H.; Yu, H.; Liu, M.F.; Du, D.; Sun, S.L.; Yang, H.C.; Wang, Y.M.; Ye, W.; Yang, L.Z.; Zhu, D.L.; Jiang, C.L.; Peng, H.S. HP-beta-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia-reperfusion injury in rats. N-S Arch Pharmacol., 2013, 386(1), 61-70.
61. Jose, S.; Sowmya, S.; Cinu, T.A.; Aleykutty, N.A.; Thomas, S.; Souto, E.B. Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. Eur. J. Pharm. Sci., 2014, 63, 29-35.
62. Wang, Z.H.; Wang, Z.Y.; Sun, C.S.; Wang, C.Y.; Jiang, T.Y.; Wang, S.L. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials, 2010, 31(5), 908-915.
63. Chang, J.; Paillard, A.; Passirani, C.; Morille, M.; Benoit, J.P.; Betbeder, D.; Garcion, E. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm. Res. Dordr., 2012, 29(6), 1495-1505.
64. Zhang, L.; Han, L.M.; Qin, J.; Lu, W.Y.; Wang, J.X. The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain. Pharm. Res. Dordr., 2013, 30(10), 2560-2572.
65. Tian, W.; Ying, X.; Du, J.; Guo, J.; Men, Y.; Zhang, Y.; Li, R.J.; Yao, H.J.; Lou, J.N.; Zhang, L.R.; Lu, W.L. Enhanced efficacy of functionalized epiru-bicin liposomes in treating brain glioma-bearing rats. Eur. J. Pharm. Sci., 2010, 41(2), 232-243.
66. Sawant, K.K.; Dodiya, S.S. Recent advances and patents on solid lipid nanoparticles. Recent Pat. Drug Deliv. Formul., 2008, 2(2), 120-135.
67. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 1994, 54(4), 987-992.
68. Blasi, P.; Schoubben, A.; Traina, G.; Manfroni, G.; Barberini, L.; Alberti, P.F.; Cirotto, C.; Ricci, M. Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int. J. Pharmaceut., 2013, 454(1), 316-323.
69. Patel, M.; Souto, E.B.; Singh, K.K. Advances in brain drug targeting and delivery: Limitations and challenges of solid lipid nanoparticles. Expert Opin. Drug Deliv, 2013, 10(7), 889-905.
70. Date, A.A.; Vador, N.; Jagtap, A.; Nagarsenker, M.S. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: Fabrication, characterization and evaluation for oral drug delivery. Nanotechnol., 2011, 22(27), 275102.
71. Tamaru, M.; Akita, H.; Kajimoto, K.; Sato, Y.; Hatakeyama, H.; Harashima, H. An apolipoprotein E modified liposomal nanoparticle: Ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells. Int. J. Pharmaceut., 2014, 465(1-2), 77-82.
72. Tamaru, M.; Akita, H.; Nakatani, T.; Kajimoto, K.; Sato, Y.; Hatakeyama, H.; Harashima, H. Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain. Int. J. Nanomed., 2014, 9, 4267-4276.
73. Re, F.; Cambianica, I.; Zona, C.; Sesana, S.; Gregori, M.; Rigolio, R.; La Ferla, B.; Nicotra, F.; Forloni, G.; Cagnotto, A.; Salmona, M.; Masserini, M.; Sancini, G. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomed. Nanotechnol., 2011, 7(5), 551-559.
74. Zong, T.L.; Mei, L.; Gao, H.L.; Shi, K.R.; Chen, J.T.; Wang, Y.; Zhang, Q.Y.; Yang, Y.T.; He, Q. Enhanced glioma targeting and penetration by dual-targeting liposome co-modified with T7 and TAT. J. Pharm. Sci. US, 2014, 103(12), 3891-3901.
75. Mourtas, S.; Lazar, A.N.; Markoutsa, E.; Duyckaerts, C.; Antimisiaris, S.G. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur. J. Med. Chem., 2014, 80, 175-183.
76. Chirio, D.; Gallarate, M.; Peira, E.; Battaglia, L.; Muntoni, E.; Riganti, C.; Biasibetti, E.; Capucchio, M.T.; Valazza, A.; Panciani, P.; Lanotte, M.; An-novazzi, L.; Caldera, V.; Mellai, M.; Filice, G.; Corona, S.; Schiffer, D. Posi-tive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. Eur. J. Pharm. Biopharm. Official J Arbeitsgemein-schaft fur Pharmazeutische Verfahrenstechnike.V, 2014, 88(3), 746-758.
77. Battaglia, L.; Gallarate, M.; Peira, E.; Chirio, D.; Muntoni, E.; Biasibetti, E.; Capucchio, M.T.; Valazza, A.; Panciani, P.P.; Lanotte, M.; Schiffer, D.; An-novazzi, L.; Caldera, V.; Mellai, M.; Riganti, C. Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: Preliminary in vitro studies. J. Pharm. Sci., 2014, 103(7), 2157-2165.
78. Dhawan, S.; Kapil, R.; Singh, B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J. Pharm. Pharmacol., 2011, 63(3), 342-351.
79. Martins, S.; Tho, I.; Reimold, I.; Fricker, G.; Souto, E.; Ferreira, D.; Brandl, M. Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. Int. J. Pharm., 2012, 439(1-2), 49-62.
80. Martins, S.M.; Sarmento, B.; Nunes, C.; Lucio, M.; Reis, S.; Ferreira, D.C. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur. J. Pharm. Biopharm. Official J. Ar-beitsgemeinschaft fur Pharmazeutische Verfahrenstechnike.V, 2013, 85(3 Pt A), 488-502.
81. Lim, W.M.; Rajinikanth, P.S.; Mallikarjun, C.; Kang, Y.B. Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. Int. J. Nanomed., 2014, 9, 2117-2126.
82. Liu, K.S.; Wen, C.J.; Yen, T.C.; Sung, K.C.; Ku, M.C.; Wang, J.J.; Fang, J.Y. Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting. Nanotechnol., 2012, 23(9), 095103.
83. Tsai, M.J.; Wu, P.C.; Huang, Y.B.; Chang, J.S.; Lin, C.L.; Tsai, Y.H.; Fang, J.Y. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int. J. Pharm., 2012, 423(2), 461-470.
84. Guo, J.T.; Waknine-Grinberg, J.H.; Mitchell, A.J.; Barenholz, Y.; Golenser, J. Reduction of Experimental cerebral malaria and its related proinflamma-tory responses by the novel liposome-based beta-methasone nanodrug. Bio. Med. Res. Int., 2014, (2014), Article ID 292471.
85. Kizelsztein, P.; Ovadia, H.; Garbuzenko, O.; Sigal, A.; Barenholz, Y. PEGylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2009, 213(1-2), 20-25.
86. Verreault, M.; Strutt, D.; Masin, D.; Anantha, M.; Waterhouse, D.; Yapp, D.T.; Bally, M.B. Irinophore C (TM), a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. J. Control. Release, 2012, 158(1), 34-43.
87. Kuo, Y.C.; Su, F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacry-late-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm, 2007, 340(1-2), 143-152.
88. Batrakova, E.V.; Miller, D.W.; Li, S.; Alakhov, V.Y.; Kabanov, A.V.; Elm-quist, W.F. Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies. J. Pharmacol. Exp. Therap., 2001, 296(2), 551-557.
89. Kim, J.Y.; Choi, W.I.; Kim, Y.H.; Tae, G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials, 2013, 34(4), 1170-1178.
90. Liu, J.S.; Wang, J.H.; Zhou, J.; Tang, X.H.; Xu, L.; Shen, T.; Wu, X.Y.; Hong, Z. Enhanced brain delivery of lamotrigine with pluronic((R)) P123-based nanocarrier. Int. J. Nanomed., 2014, 9, 3923-3935.
91. Saxena, V.; Hussain, M.D. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme. Colloid. Surf. B, Biointerface., 2013, 112, 350-355.
92. Zheng, S.; Xie, Y.; Li, Y.; Li, L.; Tian, N.; Zhu, W.; Yan, G.; Wu, C.; Hu, H. Development of high drug-loading nanomicelles targeting steroids to the brain. Int. J. Nanomed., 2014, 9, 55-66.
93. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin- and transfer-rin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. biopharm. Official J. Arbeitsge-meinschaft fur Pharmazeutische Verfahrenstechnike.V, 2009, 71(2), 251-256.
94. Yang, H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res., 2010, 27(9), 1759-1771.
95. Sarin, H.; Kanevsky, A.S.; Wu, H.T.; Brimacombe, K.R.; Fung, S.H.; Sousa, A.A.; Auh, S.; Wilson, C.M.; Sharma, K.; Aronova, M.A.; Leapman, R.D.; Griffiths, G.L.; Hall, M.D. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Translational Med., 2008, 6, 80.
96. Mishra, M.K.; Beaty, C.A.; Lesniak, W.G.; Kambhampati, S.P.; Zhang, F.; Wilson, M.A.; Blue, M.E.; Troncoso, J.C.; Kannan, S.; Johnston, M.V.; Baumgartner, W.A.; Kannan, R.M. Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest. ACS Nano, 2014, 8(3), 2134-2147.
97. Li, Y.; He, H.; Jia, X.; Lu, W.L.; Lou, J.; Wei, Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials, 2012, 33(15), 3899-3908.
98. Nyitrai, G.; Keszthelyi, T.; Bota, A.; Simon, A.; Toke, O.; Horvath, G.; Pal, I.; Kardos, J.; Heja, L. Sodium selective ion channel formation in living cell membranes by polyamidoamine dendrimer. Biochim. Biophys. Acta, 2013, 1828(8), 1873-1880.
99. Huang, S.; Li, J.; Han, L.; Liu, S.; Ma, H.; Huang, R.; Jiang, C. Dual targeting effect of angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials, 2011, 32(28), 6832-6838.
100. Somani, S.; Blatchford, D.R.; Millington, O.; Stevenson, M.L.; Dufes, C. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. J. Control. Release, 2014, 188, 78-86.
101. Gao, X.; Qian, J.; Zheng, S.; Xiong, Y.; Man, J.; Cao, B.; Wang, L.; Ju, S.; Li, C. Up-regulating blood brain barrier permeability of nanoparticles via multivalent effect. Pharm. Res., 2013, 30(10), 2538-2548.
102. Voigt, N.; Henrich-Noack, P.; Kockentiedt, S.; Hintz, W.; Tomas, J.; Sabel, B.A. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles. Eur. J. Pharma. Biopharm. Official J. Ar-beitsgemeinschaft fur Pharmazeutische Verfahrenstechnike. V, 2014, 87(1), 19-29.
103. Kulkarni, P.V.; Roney, C.A.; Antich, P.P.; Bonte, F.J.; Raghu, A.V.; Aminabhavi, T.M. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wiley Interdisciplin. Rev. Nanomed. Nanobiotechnol., 2010, 2(1), 35-47.
104. Lin, Y.; Pan, Y.; Shi, Y.; Huang, X.; Jia, N.; Jiang, J.Y. Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain. Nanotechnology, 2012, 23(16), 165101.
105. Alexiou, C.; Arnold, W.; Klein, R.J.; Parak, F.G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lubbe, A.S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res., 2000, 60(23), 6641-6648.
106. Dilnawaz, F.; Singh, A.; Mohanty, C.; Sahoo, S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials, 2010, 31(13), 3694-3706.
107. Singh, R.; Lillard, J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86(3), 215-223.
108. Veiseh, O.; Gunn, J.W.; Zhang, M.Q. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev., 2010, 62(3), 284-304.
109. Zhen, Z.P.; Xie, J. Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging. Theranostics, 2012, 2(1), 45-54.
110. Bourrinet, P.; Bengele, H.H.; Bonnemain, B.; Dencausse, A.; Idee, J.M.; Jacobs, P.M.; Lewis, J.M. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Investigative Radiol., 2006, 41(3), 313-24.
111. Wang, J.; Chen, Y.; Chen, B.; Ding, J.; Xia, G.; Gao, C.; Cheng, J.; Jin, N.; Zhou, Y.; Li, X.; Tang, M.; Wang, X.M. Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int. J. Nanomed., 2010, 5, 861-866.
112. Chertok, B.; David, A.E.; Huang, Y.; Yang, V.C. Glioma selectivity of magnetically targeted nanoparticles: A role of abnormal tumor hydrodynamics. J. Control Release, 2007, 122(3), 315-323.
113. Pilakka-Kanthikeel, S.; Atluri, V.S.; Sagar, V.; Saxena, S.K.; Nair, M. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: An in-vitro study. PloS one, 2013, 8(4), e62241.
114. Yan, F.; Wang, Y.; He, S.; Ku, S.; Gu, W.; Ye, L. Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood-brain barrier. J. Mater. Sci. Mater. Med., 2013, 24(10), 2371-2379.
115. Kirthivasan, B.; Singh, D.; Bommana, M.M.; Raut, S.L.; Squillante, E.; Sadoqi, M. Active brain targeting of a fluorescent P-gp substrate using polymeric magnetic nanocarrier system. Nanotechnology, 2012, 23(25), 255102.
116. Liu, D.F.; Qian, C.; An, Y.L.; Chang, D.; Ju, S.H.; Teng, G.J. Magnetic resonance imaging of post-ischemic blood-brain barrier damage with PEGylated iron oxide nanoparticles. Nanoscale, 2014, 6(24), 15161-15167.
117. Ding, H.; Sagar, V.; Agudelo, M.; Pilakka-Kanthikeel, S.; Atluri, V.S.; Raymond, A.; Samikkannu, T.; Nair, M.P. Enhanced blood-brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology, 2014, 25(5), 055101.
118. Riviere, C.; Martina, M.S.; Tomita, Y.; Wilhelm, C.; Tran Dinh, A.; Menager, C.; Pinard, E.; Lesieur, S.; Gazeau, F.; Seylaz, J. Magnetic targeting of nanometric magnetic fluid loaded liposomes to specific brain intravascular areas: A dynamic imaging study in mice. Radiology, 2007, 244(2), 439-448.
119. Jenkins, S.I.; Pickard, M.R.; Granger, N.; Chari, D.M. Magnetic nanoparticle-mediated gene transfer to oligodendrocyte precursor cell transplant populations is enhanced by magnetofection strategies. ACS Nano, 2011, 5(8), 6527-6538.
120. Chertok, B.; David, A.E.; Yang, V.C. Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials, 2011, 32(26), 6245-6253.
121. Wang, J.T.; Rubio, N.; Kafa, H.; Venturelli, E.; Fabbro, C.; Menard-Moyon, C.; Da Ros, T.; Sosabowski, J.K.; Lawson, A.D.; Robinson, M.K.; Prato, M.; Bianco, A.; Festy, F.; Preston, J.E.; Kostarelos, K.; Al-Jamal, K.T. Kinetics of functionalised carbon nanotube distribution in mouse brain after systemic injection: Spatial to ultra-structural analyses. J. Control. Release, 2016, 224, 22-32.
122. Kafa, H.; Wang, J.T.; Rubio, N.; Klippstein, R.; Costa, P.M.; Hassan, H.A.; Sosabowski, J.K.; Bansal, S.S.; Preston, J.E.; Abbott, N.J.; Al-Jamal, K.T. Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood-brain barrier in vitro and in vivo. J. Control. Release, 2016, 225, 217-229.
123. Feng, S.; Lu, L.; Zan, X.; Wu, Y.; Lin, Y.; Wang, Q. Genetically engineered plant viral nanoparticles direct neural cells differentiation and orientation. Langmuir: ACS J. Surf. Coll., 2015, 31(34), 9402-9409.
124. Niehl, A.; Appaix, F.; Bosca, S.; Van der Sanden, B.; Nicoud, J.F.; Bolze, F.; Heinlein, M. Fluorescent Tobacco mosaic virus-derived bio-nanoparticles for intravital two-photon imaging. Front. Plant Sci., 2015, 6, 1244.
125. Shriver, L.P.; Koudelka, K.J.; Manchester, M. Viral nanoparticles associate with regions of inflammation and blood brain barrier disruption during CNS infection. J. Neuroimmunol, 2009, 211(1-2), 66-72.
126. Kanwar, J.R.; Sun, X.; Punj, V.; Sriramoju, B.; Mohan, R.R.; Zhou, S.F.; Chauhan, A.; Kanwar, R.K. Nanoparticles in the treatment and diagnosis of neurological disorders: Untamed dragon with fire power to heal. Nanomed. Nanotechnol. Biol. Med., 2012, 8(4), 399-414.
127. Daniel, M.C.; Astruc, D. Gold nanoparticles: Assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev., 2004, 104(1), 293-346.
128. Lopez-Viota, J.; Mandal, S.; Delgado, A.V.; Toca-Herrera, J.L.; Moller, M.; Zanuttin, F.; Balestrino, M.; Krol, S. Electrophoretic characterization of gold nanoparticles functionalized with human serum albumin (HSA) and creatine. J. Coll. Interface Sci., 2009, 332(1), 215-223.
129. Gromnicova, R.; Davies, H.A.; Sreekanthreddy, P.; Romero, I.A.; Lund, T.; Roitt, I.M.; Phillips, J.B.; Male, D.K. Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PloS one, 2013, 8(12), e81043.
130. Shilo, M.; Motiei, M.; Hana, P.; Popovtzer, R. Transport of nanoparticles through the blood-brain barrier for imaging and therapeutic applications. Nanoscale, 2014, 6(4), 2146-2152.
131. Wang, P.H.; Liu, H.L.; Hsu, P.H.; Lin, C.Y.; Wang, C.R.; Chen, P.Y.; Wei, K.C.; Yen, T.C.; Li, M.L. Gold-nanorod contrast-enhanced photoacoustic micro-imaging of focused-ultrasound induced blood-brain-barrier opening in a rat model. J. Biomed. Optics, 2012, 17(6), 061222.
132. Bae, S.W.; Tan, W.; Hong, J.I. Fluorescent dye-doped silica nanoparticles: New tools for bioapplications. Chem. Commun., 2012, 48(17), 2270-2282.
133. Ku, S.; Yan, F.; Wang, Y.; Sun, Y.; Yang, N.; Ye, L. The blood-brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem. Biophys. Res. Commun., 2010, 394(4), 871-876.
134. Stachowiak, E.K.; Roy, I.; Lee, Y.W.; Capacchietti, M.; Aletta, J.M.; Prasad, P.N.; Stachowiak, M.K. Targeting novel integrative nuclear FGFR1 signaling by nanoparticle-mediated gene transfer stimulates neurogenesis in the adult brain. Integrative Biol. Quantitative Biosci. Nano Macro, 2009, 1(5-6), 394-403.
135. Wang, C.; Gao, X.; Su, X. In vitro and in vivo imaging with quantum dots. Analyt. Bioanalyt. Chem., 2010, 397(4), 1397-1415.
136. Larson, D.R.; Zipfel, W.R.; Williams, R.M.; Clark, S.W.; Bruchez, M.P.; Wise, F.W.; Webb, W.W. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science, 2003, 300(5624), 1434-1436.
137. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 2005, 307(5709), 538-544.
138. Weng, K.C.; Hashizume, R.; Noble, C.O.; Serwer, L.P.; Drummond, D.C.; Kirpotin, D.B.; Kuwabara, A.M.; Chao, L.X.; Chen, F.F.; James, C.D.; Park, J.W. Convection-enhanced delivery of targeted quantum dot-immuno-liposome hybrid nanoparticles to intracranial brain tumor models. Nano-medicine (Lond), 2013, 8(12), 1913-1925.
139. Wen, C.J.; Zhang, L.W.; Al-Suwayeh, S.A.; Yen, T.C.; Fang, J.Y. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int. J. Nanomed., 2012, 7, 1599-611.
140. Bakalova, R.; Zhelev, Z.; Kokuryo, D.; Spasov, L.; Aoki, I.; Saga, T. Chemical nature and structure of organic coating of quantum dots is crucial for their application in imaging diagnostics. Int. J. Nanomed., 2011, 6, 1719-1732.
141. Heckman, K.L.; DeCoteau, W.; Estevez, A.; Reed, K.J.; Costanzo, W.; Sanford, D.; Leiter, J.C.; Clauss, J.; Knapp, K.; Gomez, C.; Mullen, P.; Rathbun, E.; Prime, K.; Marini, J.; Patchefsky, J.; Patchefsky, A.S.; Hailstone, R.K.; Erlichman, J.S. Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain. Acs Nano, 2013, 7(12), 10582-10596.
142. Motaln, H.; Schichor, C.; Lah, T.T. Human mesenchymal stem cells and their use in cell-based therapies. Cancer, 2010, 116(11), 2519-2530.
143. Sonabend, A.M.; Ulasov, I.V.; Tyler, M.A.; Rivera, A.A.; Mathis, J.M.; Lesniak, M.S. Mesenchymal stem cells effectively deliver an oncolytic ade-novirus to intracranial glioma. Stem Cell., 2008, 26(3), 831-841.
144. Roger, M.; Clavreul, A.; Venier-Julienne, M.C.; Passirani, C.; Sindji, L.; Schiller, P.; Montero-Menei, C.; Menei, P. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials, 2010, 31(32), 8393-8401.